Clinical utility of natural killer cells in cancer therapy and transplantation

Seminars in Immunology

Volumn 26, Issue 2, 2014, Pages 161-172

  Knorr, David A ^a   Bachanova, Veronika ^a   Verneris, Michael R ^a   Miller, Jeffrey S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Acute myeloid leukemia; Adoptive cell therapy; Immunomodulation; Immunotherapy; NK cells

Indexed keywords

CD16 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CYCLINE; CYCLOPHOSPHAMIDE; FC RECEPTOR; FLUDARABINE; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 21; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NATURAL KILLER CELL RECEPTOR; RITUXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOIMMUNITY; ANTIGEN SPECIFICITY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CANCER TRANSPLANTATION; CELL ACTIVATION; CELL EXPANSION; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; CYTOMEGALOVIRUS; CYTOTOXICITY; EX VIVO STUDY; GOOD MANUFACTURING PRACTICE; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNOGENETICS; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; PROTEIN CROSS LINKING; REGULATORY T LYMPHOCYTE; REVIEW; ADOPTIVE IMMUNOTHERAPY; BIOLOGICAL THERAPY; CYTOLOGY; IMMUNOLOGY; METABOLISM; NEOPLASMS; PROCEDURES; TRANSPLANTATION;

CELL- AND TISSUE-BASED THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; NEOPLASMS;

EID: 84897965451     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2014.02.002     Document Type: Review

References (152)

1. Waldmann Ta., Lugli E., Roederer M., Perera L.P., Smedley J.V., Macallister R.P., et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 2011, 117:4787-4795.
2. Waldmann T.A., Dubois S., Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 2001, 14:105-110.
3. Becknell B., Caligiuri M.A. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 2005, 86:209-239.
4. Weiner L.M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010, 10:317-327.
5. Romagne F., Andre P., Spee P., Zahn S., Anfossi N., Gauthier L., et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009, 114:2667-2677.
6. Sliwkowski M.X., Mellman I. Antibody therapeutics in cancer. Science 2013, 341:1192-1198.
7. Ljunggren H.-G., Malmberg K.-J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007, 7:329-339.
8. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., Dudley M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008, 8:299-308.
9. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733.
10. June C.H., Blazar B.R., Riley J.L. Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 2009, 9:704-716.
11. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368:1509-1518.
12. Kiessling R., Klein E., Wigzell H. Natural killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975, 5:112-117.
13. Rezaei N., Mahmoudi E., Aghamohammadi A., Das R., Nichols K.E. X-linked lymphoproliferative syndrome: a genetic condition typified by the triad of infection, immunodeficiency and lymphoma. Br J Haematol 2011, 152:13-30.
14. Mace E.M., Hsu A.P., Monaco-Shawver L., Makedonas G., Rosen J.B., Dropulic L., et al. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56bright subset. Blood 2013, 121:2669-2677.
15. Biron C.A., Byron K.S., Sullivan J.L. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989, 320:1731-1735.
16. Freud A.G., Caligiuri M.A. Human natural killer cell development. Immunol Rev 2006, 214:56-72.
17. Huntington N.D., Legrand N., Alves N.L., Jaron B., Weijer K., Plet A., et al. IL-15 trans-presentation promotes human NK cell development and diff erentiation in vivo. Cell Differ 2009, 206:25-34.
18. Farag S.S., Caligiuri Ma. Human natural killer cell development and biology. Blood Rev 2006, 20:123-137.
19. Vacca P., Vitale C., Montaldo E., Conte R., Cantoni C., Fulcheri E., et al. CD34+ hematopoietic precursors are present in human decidua and differentiate into natural killer cells upon interaction with stromal cells. Proc Natl Acad Sci U S A 2011, 108:2402-2407.
20. Huntington N.D., Vosshenrich C.A., Di Santo J.P. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 2007, 7:703-714.
21. Fauriat C., Long E.O., Ljunggren H.G., Bryceson Y.T. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 2010, 115:2167-2176.
22. Kennedy M.K., Glaccum M., Brown S.N., Butz E.A., Viney J.L., Embers M., et al. Reversible defects in natural killer and memory CD8T cell lineages in interleukin 15-deficient mice. J Exp Med 2000, 191:771-780.
23. Lodolce J.P., Boone D.L., Chai S., Swain R.E., Dassopoulos T., Trettin S., et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998, 9:669-676.
24. Imada K., Bloom E.T., Nakajima H., Horvath-Arcidiacono J.A., Udy G.B., Davey H.W., et al. Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med 1998, 188:2067-2074.
25. Eidenschenk C., Jouanguy E., Alcaïs A., Mention J.-J., Pasquier B., Fleckenstein I.M., et al. Familial NK cell deficiency associated with impaired IL-2- and IL-15-dependent survival of lymphocytes. J Immunol 2006, 177:8835-8843.
26. Vilches C., Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Ann Rev Immunol 2002, 20:217-251.
27. Moretta A., Vitale M., Bottino C., Orengo A.M., Morelli L., Augugliaro R., et al. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med 1993, 178:597-604.
28. Moretta A., Sivori S., Vitale M., Pende D., Morelli L., Augugliaro R., et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 1995, 182:875-884.
29. Moretta A., Bottino C., Vitale M., Pende D., Biassoni R., Mingari M.C., et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996, 14:619-648.
30. Valiante N.M., Uhrberg M., Shilling H.G., Lienert-Weidenbach K., Arnett K.L., D'Andrea A., et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 1997, 7:739-751.
31. Chan H.W., Kurago Z.B., Stewart C.A., Wilson M.J., Martin M.P., Mace B.E., et al. DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J Exp Med 2003, 197:245-255.
32. Chan H.W., Miller J.S., Moore M.B., Lutz C.T. Epigenetic control of highly homologous killer Ig-like receptor gene alleles. J Immunol 2005, 175:5966-5974.
33. Cooley S., Trachtenberg E., Bergemann T.L., Saeteurn K., Klein J., Le C.T., et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009, 113:726-732.
34. Pyo C.-W., Guethlein La, Vu Q., Wang R., Abi-Rached L., Norman P.J., et al. Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Ig-like receptor locus. PLoS ONE 2010, 5:e15115.
35. Bryceson Y.T., March M.E., Ljunggren H.G., Long E.O. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 2006, 214:73-91.
36. Belanger S., Tu M.M., Rahim M.M., Mahmoud A.B., Patel R., Tai L.H., et al. Impaired natural killer cell self-education and missing-self responses in Ly49-deficient mice. Blood 2012, 120:592-602.
37. Orr M.T., Wu J., Fang M., Sigal L.J., Spee P., Egebjerg T., et al. Development and function of CD94-deficient natural killer cells. PLoS ONE 2010, 5:e15184.
38. Cosman D., Mullberg J., Sutherland C.L., Chin W., Armitage R., Fanslow W., et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001, 14:123-133.
39. Lanier L.L. NK cell recognition. Annu Rev Immunol 2005, 23:225-274.
40. Pende D., Parolini S., Pessino A., Sivori S., Augugliaro R., Morelli L., et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999, 190:1505-1516.
41. Baychelier F., Sennepin A., Ermonval M., Dorgham K., Debre P., Vieillard V. Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood 2013, 122:2935-2942.
42. Vitale M., Bottino C., Sivori S., Sanseverino L., Castriconi R., Marcenaro E., et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998, 187:2065-2072.
43. Mandelboim O., Lieberman N., Lev M., Paul L., Arnon T.I., Bushkin Y., et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001, 409:1055-1060.
44. Sivori S., Vitale M., Morelli L., Sanseverino L., Augugliaro R., Bottino C., et al. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 1997, 186:1129-1136.
45. Cosman D., Fanger N., Borges L., Kubin M., Chin W., Peterson L., et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 1997, 7:273-282.
46. Brandt C.S., Baratin M., Yi E.C., Kennedy J., Gao Z., Fox B., et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009, 206:1495-1503.
47. Pogge von Strandmann E., Simhadri V.R., von Tresckow B., Sasse S., Reiners K.S., Hansen H.P., et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007, 27:965-974.
48. Rosental B., Brusilovsky M., Hadad U., Oz D., Appel M.Y., Afergan F., et al. Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol 2011, 187:5693-5702.
49. Claus M., Meinke S., Bhat R., Watzl C. Regulation of NK cell activity by 2B4, NTB-A and CRACC. Front Biosci 2008, 13:956-965.
50. de Andrade L.F., Smyth M.J., Martinet L. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins. Immunol Cell Biol 2013, 17:95.
51. Zhang Y., Wallace D.L., de Lara C.M., Ghattas H., Asquith B., Worth A., et al. In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology 2007, 121:258-265.
52. Kim S., Poursine-Laurent J., Truscott S.M., Lybarger L., Song Y.J., Yang L., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436:709-713.
53. Anfossi N., André P., Guia S., Falk C.S., Roetynck S., Stewart C.A., et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006, 25:331-342.
54. Fernandez N.C., Treiner E., Vance R.E., Jamieson A.M., Lemieux S., Raulet D.H. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005, 105:4416-4423.
55. Tarek N., Le Luduec J.B., Gallagher M.M., Zheng J., Venstrom J.M., Chamberlain E., et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest 2012, 122:3260-3270.
56. Cooley S., Xiao F., Pitt M., Gleason M., McCullar V., Bergemann T.L., et al. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 2007, 110:578-586.
57. Foley B., Cooley S., Verneris M.R., Curtsinger J., Luo X., Waller E.K., et al. NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood 2011, 118:2784-2792.
58. Yawata M., Yawata N., Draghi M., Little A.M., Partheniou F., Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006, 203:633-645.
59. Mamessier E., Sylvain A., Thibult M.-L., Houvenaeghel G., Jacquemier J., Castellano R., et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011, 121:3609-3622.
60. Doubrovina E.S., Doubrovin M.M., Vider E., Sisson R.B., O'Reilly R.J., Dupont B., et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 2003, 171:6891-6899.
61. Mapara M.Y., Sykes M. Tolerance and cancer; mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004, 22:1136-1151.
62. Carson W.E., Ross M.E., Baiocchi R.A., Marien M.J., Boiani N., Grabstein K., et al. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro. J Clin Invest 1995, 96:2578-2582.
63. Smyth M.J., Cretney E., Kershaw M.H., Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004, 202:275-293.
64. Romee R., Schneider S.E., Leong J.W., Chase J.M., Keppel C.R., Sullivan R.P., et al. Cytokine activation induces human memory-like NK cells. Blood 2012, 120:4751-4760.
65. Herberman R.B., Nunn M.E., Lavrin D.H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 1975, 16:216-229.
66. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
67. Farag S.S., Bacigalupo A., Eapen M., Hurley C., Dupont B., Caligiuri M.A., et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 2006, 12:876-884.
68. Davies S.M., Ruggieri L., DeFor T., Wagner J.E., Weisdorf D.J., Miller J.S., et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002, 100:3825-3827.
69. Lowe E.J., Turner V., Handgretinger R., Horwitz E.M., Benaim E., Hale G.A., et al. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br J Haematol 2003, 123:323-326.
70. Kroger N., Binder T., Zabelina T., Wolschke C., Schieder H., Renges H., et al. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 2006, 82:1024-1030.
71. Foley B., De Santis D., Lathbury L., Christiansen F., Witt C. KIR2DS1-mediated activation overrides NKG2A-mediated inhibition in HLA-C C2-negative individuals. Int Immunol 2008, 20:555-563.
72. Venstrom J.M., Pittari G., Gooley T.A., Chewning J.H., Spellman S., Haagenson M., et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012, 367:805-816.
73. McQueen K.L., Dorighi K.M., Guethlein L.A., Wong R., Sanjanwala B., Parham P. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol 2007, 68:309-323.
74. Stringaris K., Adams S., Uribe M., Eniafe R., Wu C.O., Savani B.N., et al. Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol Blood Marrow Transplant 2010, 16:1257-1264.
75. Nguyen S., Dhedin N., Vernant J.P., Kuentz M., Al Jijakli A., Rouas-Freiss N., et al. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 2005, 105:4135-4142.
76. Vago L., Forno B., Sormani M.P., Crocchiolo R., Zino E., Di Terlizzi S., et al. Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood 2008, 112:3488-3499.
77. Kaminski B.A., Kadereit S., Miller R.E., Leahy P., Stein K.R., Topa D.A., et al. Reduced expression of NFAT-associated genes in UCB versus adult CD4+ T lymphocytes during primary stimulation. Blood 2003, 102:4608-4617.
78. Nguyen S., Kuentz M., Vernant J.P., Dhedin N., Bories D., Debre P., et al. Involvement of mature donor T cells in the NK cell reconstitution after haploidentical hematopoietic stem-cell transplantation. Leukemia 2008, 22:344-352.
79. Shilling H.G., McQueen K.L., Cheng N.W., Shizuru J.A., Negrin R.S., Parham P. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 2003, 101:3730-3740.
80. Fehniger T.A., Cooper M.A., Nuovo G.J., Cella M., Facchetti F., Colonna M., et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003, 101:3052-3057.
81. Lopez-Verges S., Milush J.M., Schwartz B.S., Pando M.J., Jarjoura J., York V.A., et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A 2011, 108:14725-14732.
82. Elmaagacli A.H., Steckel N.K., Koldehoff M., Hegerfeldt Y., Trenschel R., Ditschkowski M., et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 2011, 118:1402-1412.
83. Green M.L., Leisenring W.M., Xie H., Walter R.B., Mielcarek M., Sandmaier B.M., et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 2013, 122:1316-1324.
84. Manjappa S., Bhamidipati P.K., Stokerl-Goldstein K.E., Dipersio J.F., Uy G.L., Westervelt P., et al. Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. Biol Blood Marrow Transplant 2014, 20:46-52.
85. Foley B., Cooley S., Verneris M.R., Pitt M., Curtsinger J., Luo X., et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 2012, 119:2665-2674.
86. Foley B., Cooley S., Verneris M.R., Curtsinger J., Luo X., Waller E.K., et al. Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol 2012, 189:5082-5088.
87. Sun J.C., Beilke J.N., Lanier L.L. Adaptive immune features of natural killer cells. Nature 2009, 457:557-561.
88. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
89. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
90. van der Most R.G., Currie A.J., Mahendran S., Prosser A., Darabi A., Robinson B.W., et al. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother 2009, 58:1219-1228.
91. Baba J., Watanabe S., Saida Y., Tanaka T., Miyabayashi T., Koshio J., et al. Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia. Blood 2012, 120:2417-2427.
92. Burns L.J., Weisdorf D.J., DeFor T.E., Vesole D.H., Repka T.L., Blazar B.R., et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant 2003, 32:177-186.
93. Rubnitz J.E., Inaba H., Ribeiro R.C., Pounds S., Rooney B., Bell T., et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010, 28:955-959.
94. Curti A., Ruggeri L., D'Addio A., Bontadini A., Dan E., Motta M.R., et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 2011, 118:3273-3279.
95. Sim G.C., Martin-Orozco N., Jin L., Yang Y., Wu S., Washington E., et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest 2013, 2.
96. Matsuoka K., Koreth J., Kim H.T., Bascug G., McDonough S., Kawano Y., et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 2013, 5:3005265.
97. Geller M.A., Cooley S., Judson P.L., Ghebre R., Carson L.F., Argenta P.A., et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011, 13:98-107.
98. Iliopoulou E.G., Kountourakis P., Karamouzis M.V., Doufexis D., Ardavanis A., Baxevanis C.N., et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010, 59:1781-1789.
99. Rizzieri D.A., Storms R., Chen D.F., Long G., Yang Y., Nikcevich D.A., et al. Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:1107-1114.
100. Cheng M., Chen Y., Xiao W., Sun R., Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 2013, 10:230-252.
101. Bachanova V., Burns L.J., McKenna D.H., Curtsinger J., Panoskaltsis-Mortari A., Lindgren B.R., et al. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother 2010, 59:1739-1744.
102. Lundqvist A., Berg M., Smith A., Childs R.W. Bortezomib treatment to potentiate the anti-tumor immunity of ex-vivo expanded adoptively infused autologous natural killer cells. J Cancer 2011, 2:383-385.
103. Skeate R., Singh C., Cooley S., Geller M., Northouse J., Welbig J., et al. Hemolytic anemia due to passenger lymphocyte syndrome in solid malignancy patients treated with allogeneic natural killer cell products. Transfusion 2013, 53:419-423.
104. Rodella L., Zamai L., Rezzani R., Artico M., Peri G., Falconi M., et al. Interleukin 2 and interleukin 15 differentially predispose natural killer cells to apoptosis mediated by endothelial and tumour cells. Br J Haematol 2001, 115:442-450.
105. Fujisaki H., Kakuda H., Shimasaki N., Imai C., Ma J., Lockey T., et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009, 69:4010-4017.
106. Shah N., Martin-Antonio B., Yang H., Ku S., Lee D.A., Cooper L.J., et al. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS ONE 2013, 8:0076781.
107. Denman C.J., Senyukov V.V., Somanchi S.S., Phatarpekar P.V., Kopp L.M., Johnson J.L., et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 2012, 7:e30264.
108. Somanchi S.S., Somanchi A., Cooper L.J., Lee D.A. Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood 2012, 119:5164-5172.
109. Fujisaki H., Kakuda H., Imai C., Mullighan C.G., Campana D. Replicative potential of human natural killer cells. Br J Haematol 2009, 145:606-613.
110. Berg M., Lundqvist A., McCoy P., Samsel L., Fan Y., Tawab A., et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009, 11:341-355.
111. North J., Bakhsh I., Marden C., Pittman H., Addison E., Navarrete C., et al. Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation. J Immunol 2007, 178:85-94.
112. Sabry M., Tsirogianni M., Bakhsh I.A., North J., Sivakumaran J., Giannopoulos K., et al. Leukemic priming of resting NK cells is killer Ig-like receptor independent but requires CD15-mediated CD2 ligation and natural cytotoxicity receptors. J Immunol 2011, 187:6227-6234.
113. Sabry M., Lowdell M.W. Tumor-primed nk cells: waiting for the green light. Front Immunol 2013, 4:408.
114. Cooper M.A., Yokoyama W.M. Memory-like responses of natural killer cells. Immunol Rev 2010, 235:297-305.
115. Sun J.C., Beilke J.N., Bezman N.A., Lanier L.L. Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection. J Exp Med 2011, 208:357-368.
116. Gumá M., Angulo A., Vilches C., Gómez-Lozano N., Malats N., López-Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 2004, 104:3664-3671.
117. Gumá M., Budt M., Sáez A., Brckalo T., Hengel H., Angulo A., et al. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood 2006, 107:3624-3631.
118. Bjorkstrom N.K., Lindgren T., Stoltz M., Fauriat C., Braun M., Evander M., et al. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J Exp Med 2011, 208:13-21.
119. Petitdemange C., Becquart P., Wauquier N., Beziat V., Debre P., Leroy E.M., et al. Unconventional repertoire profile is imprinted during acute chikungunya infection for natural killer cells polarization toward cytotoxicity. PLoS Pathog 2011, 7:22.
120. Scott A.M., Wolchok J.D., Old L.J. Antibody therapy of cancer. Nat Rev Cancer 2012, 12:278-287.
121. Hsi E.D., Steinle R., Balasa B., Szmania S., Draksharapu A., Shum B.P., et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008, 14:2775-2784.
122. Kohrt H.E., Houot R., Weiskopf K., Goldstein M.J., Scheeren F., Czerwinski D., et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012, 122:1066-1075.
123. Benson D.M., Bakan C.E., Zhang S., Collins S.M., Liang J., Srivastava S., et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 2011, 118:6387-6391.
124. Parihar R., Nadella P., Lewis A., Jensen R., De Hoff C., Dierksheide J.E., et al. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res 2004, 10:5027-5037.
125. Parihar R., Dierksheide J., Hu Y., Carson W.E. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest 2002, 110:983-992.
126. Romee R., Foley B., Lenvik T., Wang Y., Zhang B., Ankarlo D., et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 2013, 121:3599-3608.
127. Lajoie L., Congy-Jolivet N., Bolzec A., Gouilleux-Gruart V., Sicard E., Sung H.C., et al. ADAM17-mediated shedding of Fc(RIIIA on human NK cells: identification of the cleavage site and relationship with activation. J Immunol 2013, 192(2):741-751.
128. Arribas J., Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des 2009, 15:2319-2335.
129. Borgerding A., Hasenkamp J., Engelke M., Burkhart N., Trumper L., Wienands J., et al. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression. Exp Hematol 2010, 38:213-221.
130. Kohrt H.E., Thielens A., Marabelle A., Sagiv-Barfi I., Sola C., Chanuc F., et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 2013, 10:10.
131. Knorr D.A., Kaufman D.S. Pluripotent stem cell-derived natural killer cells for cancer therapy. Transl Res 2010, 156:147-154.
132. Grzywacz B., Kataria N., Sikora M., Oostendorp R.A., Dzierzak E.A., Blazar B.R., et al. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood 2006, 108:3824-3833.
133. Spanholtz J., Preijers F., Tordoir M., Trilsbeek C., Paardekooper J., de Witte T., et al. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS ONE 2011, 6:16.
134. Yoon S.R., Lee Y.S., Yang S.H., Ahn K.H., Lee J.H., Kim D.Y., et al. Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant 2010, 45:1038-1046.
135. Arai S., Meagher R., Swearingen M., Myint H., Rich E., Martinson J., et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008, 10:625-632.
136. Woll P.S., Grzywacz B., Tian X., Marcus R.K., Knorr D.A., Verneris M.R., et al. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood 2009, 113:6094-6101.
137. Knorr D.A., Ni Z., Hermanson D., Hexum M.K., Bendzick L., Cooper L.J., et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med 2013, 2:274-283.
138. Themeli M., Kloss C.C., Ciriello G., Fedorov V.D., Perna F., Gonen M., et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol 2013, 31:928-933.
139. Torikai H., Reik A., Soldner F., Warren E.H., Yuen C., Zhou Y., et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 2013, 122:1341-1349.
140. Schwartz S.D., Hubschman J.-P., Heilwell G., Franco-Cardenas V., Pan C.K., Ostrick R.M., et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 2012, 379:713-720.
141. Baeuerle P.A., Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009, 69:4941-4944.
142. Bargou R., Leo E., Zugmaier G., Klinger M., Goebeler M., Knop S., et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 321:974-977.
143. Vallera D.A., Zhang B., Gleason M.K., Oh S., Weiner L.M., Kaufman D.S., et al. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother Radiopharm 2013, 23:23.
144. Wiernik A., Foley B., Zhang B., Verneris M.R., Warlick E., Gleason M.K., et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16×33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res 2013, 19:3844-3855.
145. Gleason M.K., Verneris M.R., Todhunter D.A., Zhang B., McCullar V., Zhou S.X., et al. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther 2012, 11:2674-2684.
146. Topp M.S., Kufer P., Gökbuget N., Goebeler M., Klinger M., Neumann S., et al. Targeted therapy with the T-cell - engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in b-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011, 29:2493-2498.
147. Zamai L., Ahmad M., Bennett I.M., Azzoni L., Alnemri E.S., Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and fas ligand by immature and mature primary human NK cells. J Exp Med 1998, 188:2375-2380.
148. Benson D.M., Hofmeister C.C., Padmanabhan S., Suvannasankha A., Jagannath S., Abonour R., et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012, 120:4324-4333.
149. Sayers T.J., Brooks A.D., Koh C.Y., Ma W., Seki N., Raziuddin A., et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003, 102:303-310.
150. Lundqvist A., Abrams S.I., Schrump D.S., Alvarez G., Suffredini D., Berg M., et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 2006, 66:7317-7325.
151. Wennerberg E., Sarhan D., Carlsten M., Kaminskyy V.O., D'Arcy P., Zhivotovsky B., et al. Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling. Int J Cancer 2013, 133:1643-1652.
152. Terme M., Ullrich E., Aymeric L., Meinhardt K., Desbois M., Delahaye N., et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 2011, 71:5393-5399.